Business, energy, technology, markets and global industry news from Business News Today

SB27

PharmaDeviceNews SB27
Targeted lung cancer therapy is becoming increasingly important as Johnson & Johnson expands Rybrevant across EGFR-mutated non-small cell lung cancer treatment. Representative image.
Features & Analysis

Can Samsung Bioepis challenge Keytruda after its U.S. patent cliff begins in 2028?

Samsung Bioepis matched Keytruda in Phase 3, but an earlier FDA filing and Keytruda Qlex complicate the coming biosimilar battle.

Read More
Representative image: Samsung Bioepis’ SB27 Keytruda biosimilar trial results highlight a potentially important step toward lower-cost pembrolizumab competition in the global oncology market.
Pharma & Biotech

Samsung Bioepis SB27 meets Phase 3 endpoint as Keytruda biosimilar competition accelerates

Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.

Read More